Press release
Bronchitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the C Bronchitis Treatment Landscape. Click here to read more @ Bronchitis Pipeline Outlook [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bronchitis Pipeline Report
* In April 2025, Incyte Corporation announced a study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
* In April 2025, Kadmon, a Sanofi Company announced a Phase 2, open-label, long-term treatment and follow-up study in subjects with cGVHD who have been previously treated with belumosudil in Study KD025-208 or Study KD025-213. Subjects will not be screened.
* DelveInsight's Bronchitis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchitis treatment.
* The leading Bronchitis Companies such as Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp & Dohme Corp., Johnson & Johnson Pharmaceutical Research & Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott and others.
* Promising Bronchitis Pipeline Therapies such as BN101, TQ05105 Tablet, Belumosudil, Rituximab, Prednisone, TDI01 suspension, INCA034176, Corticosteroids and others.
Discover groundbreaking developments in Bronchitis Therapies! Gain in-depth knowledge of key Bronchitis Clinical trials, emerging drugs, and market opportunities @ Bronchitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchitis Emerging Drugs Profile
* DW 1601: Daewon Pharmaceutical
Daewon Pharmaceutical is developing DW 1601 for the treatment of Bronchitis.
The Bronchitis Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Bronchitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchitis Treatment.
* Bronchitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Bronchitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchitis Market
Stay informed about the Bronchitis Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Bronchitis Unmet Needs [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchitis Companies
Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp & Dohme Corp., Johnson & Johnson Pharmaceutical Research & Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott and others.
Bronchitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type
Bronchitis Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
Transform your understanding of the Bronchitis Pipeline! See the latest progress in drug development and clinical research @ Bronchitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bronchitis Pipeline Report
* Coverage- Global
* Bronchitis Companies- Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp & Dohme Corp., Johnson & Johnson Pharmaceutical Research & Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott and others.
* Bronchitis Pipeline Therapies- BN101, TQ05105 Tablet, Belumosudil, Rituximab, Prednisone, TDI01 suspension, INCA034176, Corticosteroids and others.
* Bronchitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Respiratory Disease Research-Access the Full Bronchitis Pipeline Analysis Today! @ Bronchitis Drugs and Companies [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Bronchitis: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
* Pipeline Therapeutics
* Comparative Analysis
* Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
* Bronchitis - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Bronchitis companies' collaborations, Licensing, Acquisition -Deal Value Trends
* Bronchitis Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
* Late Stage Products (Phase III)
* Comparative Analysis
* DW 1601: Daewon Pharmaceutical
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Inactive Products
* Comparative Analysis
* Bronchitis Key Companies
* Bronchitis Key Products
* Bronchitis- Unmet Needs
* Bronchitis- Market Drivers and Barriers
* Bronchitis- Future Perspectives and Conclusion
* Bronchitis Analyst Views
* Bronchitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchitis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bronchitis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 4000134 • Views: …
More Releases from ABNewswire
Queens Workers' Compensation Lawyer Keetick L. Sanchez Highlights Key Reasons to …
Navigating the workers' compensation process can be challenging for many injured workers. In a recent article, Queens workers' compensation lawyer Keetick L. Sanchez (https://accidentlawyer-queens.com/should-you-get-a-workers-comp-attorney/) of K L Sanchez Law Office, P.C. breaks down critical moments when hiring legal representation can make a meaningful difference in the outcome of a claim. For those unsure about their next steps after a work-related injury, Sanchez offers insight into the benefits of having legal…
Bariatric Audience Unveils Data-Driven Marketing Solution for Bariatric Surgery …
Bariatric Audience, based in Atlanta, announces a complete marketing solution to help bariatric surgery practices expand reach and drive growth. The system combines AI-driven insights, advanced lead management, and targeted campaigns to deliver measurable results. Services include SEO, tailored strategies, and pay-per-click ads, ensuring practices attract high-intent patients and build long-term authority in a competitive market.
Atlanta, GA - Oct 1, 2025 - Bariatric Audience announces the launch of a complete…
Northern Virginia Personal Injury Lawyers From Jennifer Porter Law, PLLC, Discus …
Fairfax, Virginia - Jennifer Porter Law, PLLC (https://jenniferporterlaw.com/will-my-personal-injury-case-go-to-trial-in-virginia) announces guidance for injury victims weighing settlement against trial in Virginia courts. Led by attorney Jennifer Porter, a seasoned Northern Virginia personal injury lawyer, the firm outlines how evidence, liability disputes, and court practices shape whether a claim resolves at the negotiating table or proceeds before a judge or jury.
In public remarks, Jennifer Porter emphasized that most Virginia cases settle, yet litigation…
The Kugel Law Firm Shares Guidance From New York DWI Attorneys On How New York C …
New York, NY - The Kugel Law Firm (https://thekugellawfirm.com/what-type-of-crime-is-a-dwi-in-new-york/) today released comprehensive guidance from its New York DWI attorneys detailing how New York classifies DWI offenses, what appears on criminal and driving records, and how recent record-sealing reforms affect individuals with alcohol or drug driving convictions. The announcement outlines the distinctions among misdemeanor, felony, and non-criminal violations under New York Vehicle and Traffic Law and explains the timelines for potential…
More Releases for Bronchitis
Rising Respiratory Disease Incidence Sparks Robust Growth In Bronchitis Treatmen …
The Bronchitis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Bronchitis Treatment Market?
The market for bronchitis treatments has seen robust expansion in the past few years, with projections showing an increase from $5.61 billion in 2024 to…
Acute Bronchitis Treatment Market: An In-Depth Analysis
The global Acute Bronchitis Treatment market was valued at approximately USD 6.3 billion in 2023 and is projected to reach around USD 9.9 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% during the forecast period.
Acute Bronchitis Treatment Market Overview
Acute bronchitis is a common respiratory condition characterized by inflammation of the bronchial tubes, leading to symptoms such as coughing and mucus production. The market's growth…
Bronchitis Treatment Market Statistical Forecast, Trade Analysis 2024 - 2031
DataM Intelligence has published a new research report on "Bronchitis Treatment Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF -…
Bronchitis Treatment Market Outlook, Insights, Size 2024-2033
The bronchitis treatment market size has grown strongly in recent years. It will grow from $5.25 billion in 2023 to $5.58 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising air pollution levels, cigarette smoking epidemic, increased respiratory infections, environmental and occupational exposures, lifestyle factors..
The bronchitis treatment market size is expected to see strong…
Acute Bronchitis Treatment Market: What are the key opportunities?
The report attempts to offer high-quality and accurate analysis of the global Acute Bronchitis Treatment Market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Acute Bronchitis Treatment market that are impacting their business. Readers can become aware of crucial opportunities available in the global Acute…
Bronchitis Market: Study Navigating the Future Growth Outlook
Global Bronchitis Market Report 2019 - Market Size, Share, Price, Trend and Forecast is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Bronchitis Market. Some of the key players profiled in the study are…
